Boehringer Ingelheim and Palatin Technologies today announced a global research collaboration and licensing agreement aiming ...

Privately-held dermatology specialist LEO Pharma today revealed robust growth and significantly improved profitability, ...

Japanese drugmaker Eisai today announced that its in-house-discovered and developed orexin receptor antagonist Dayvigo (brand ...

Sweden’s Board for the Assessment of Pharmaceutical Information, NBL, has clarified the regulations for online advertising ...

Brazil’s Fiocruz, through the Drug Technology Institute (Farmanguinhos), and the pharmaceutical company EMS have signed two ...

Australia’s Neurizon Therapeutics saw its shares rise 10% to A$0.16 today. after it revealed that it has been informed by the ...

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

AstraZeneca (LSE: AZN) has launched FluMist Home, the first FDA-approved influenza vaccine program that allows self- or ...

The bladder cancer market across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, China, and Japan) is projected to grow from $3 billion in 2023 to $16 billion in 2033, at a ...

Japan’s Mochida Pharmaceutical has announced that Lialda (mesalazine 600mg) the will be launched on September 8, 2025, as the NHI (National Health Insurance) Drug Price was listed on August 14, 2025.